重组人血管内皮抑制素联合SOX方案治疗晚期胃癌的临床观察.docxVIP

??

?

??

重组人血管内皮抑制素联合SOX方案治疗晚期胃癌的临床观察

?

??

?

?

?

?

?

?

?

???

?

?

?

?

?

摘要目的：观察重组人血管内皮抑制素（恩度）联合SOX方案治疗晚期胃癌疗效和安全性。方法：将165例晚期胃癌患者随机分为试验组和对照组，试验组80例，采用重组人血管内皮抑制素联合SOX方案化疗治疗。对照组85例，采用SOX方案治疗。至少两个周期后评价疗效和不良反应。结果：试验组：CR1例，PR42例，SD25例，PD12例。对照组：CR0例，PR36例，SD26例，PD23例，试验组和对照组的有效率（RR）分别为53.8%和42.4%（P=0.188），疾病控制率（DCR）分别为85%和72.9%（P=0.188），中位无疾病进展生存期（PFS）分别为15.0个月和12.0个月（P=0.000），两组主要不良反应为不同程度的骨髓抑制、胃肠道反应和周围神经炎。结论:重组人血管内皮抑制素（恩度）联合SOX方案治疗晚期胃癌疗效较单纯SOX方案化疗相对安全，疗效肯定。

关键词：血管内皮抑制素，替吉奥，奥沙利铂，晚期胃癌

【中图分类号】R735.2【文献标识码】A【文章编号】

ClinicStudyofRecombinantHumanVascularEndothelialInhibin(TU)CombinedwiththeSOXRegimentinAdvancedGastricCancerXuRong1,MaNan2(ThePeoplesHospitalofXinjiang,1DepartmentofMedicalOncology,2DepartmentofSurgicalOncology,Urumqi830000)AbstractObjectives:Weaimtoevaluatetheefficacyandsafetyofcombinationtherapyofrecombinanthumanendostatin(Endostar)andtheS-1combinedwithoxaliplatin(SOX)ingastriccancerpatients.

Methods:Inthisrandomizedcontrolledtrial,165latestagegastriccancerpatientswereassignedtotheexperimentalarmwithrecombinanthumanendostatinincombinationwithSOX(80patients)andthecontrolarmwithSOXalone(85patients).Theendpointsofthisstudyincluderesponserate(RR),progression-freesurvival(PFS),anddiseasecontrolrate(DCR).

Results:Thereisnostatisticallysignificantdifferenceinresponserate(RR)betweentheexperimentalarmandthecontrolarm(53.8%vs.42.4%,p=0.188).Thedifferenceofthetwoarmsindiseasecontrolrateisalsostatisticallyinsignificant(85.0%vs.72.9%,p=0.188).Theprogression-freesurvivalintheexperimentalarmissignificantlyhigherthanthatinthecontrolarm(15.0monthsvs.12.0months,p=0.000).Thecommonadverseeffectsincludeimmunosuppression,GIdistressandneuropathy.Thereisnostatisticaldifferenceintheincidencesofadverseeffects.

Conclusion:Combinationtherapyofrecombinanthumanendostati